TWD
ATNM icon

True Wealth Design’s Actinium Pharmaceuticals ATNM Stock Holding History

True Wealth Design’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$4 – 2575
2025
Q3 		$4 Sell
2
-22
-92% -$36 ﹤0.01% 2709
2025
Q2 		$34 Buy
24
+7
+41% +$10 ﹤0.01% 2447
2025
Q1 		$28 Buy
+17
New +$22 ﹤0.01% 2522
2024
Q4 		– Sell
-472
Closed -$888 – 1369
2024
Q3 		$888 Buy
+472
New +$1.86K ﹤0.01% 999

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

True Wealth Design's ATNM Position: Q4 2025 in Review

True Wealth Design sold out of Actinium Pharmaceuticals (ATNM) in Q4 2025, closing a stake of 2 shares — an estimated $4 sold.

True Wealth Design first reported a position in ATNM in Q3 2024 and held it in 4 quarters. The position peaked at $888 in Q3 2024. 60 funds tracked by Wall St. Rank hold ATNM as of Q4 2025.

  • True Wealth Design reported no remaining Actinium Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • True Wealth Design sold 2 Actinium Pharmaceuticals shares in Q4 2025, an estimated $4.
  • True Wealth Design first reported a position in Actinium Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • True Wealth Design's Actinium Pharmaceuticals position peaked at $888 in Q3 2024.
  • 60 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2025.

Based on True Wealth Design's 13F filing for Q4 2025, filed 8 Jan 2026.